Long-Term Outcomes From a Dose-Optimization Study of CAR T Cells in Relapsed CLL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia
J. Clin. Oncol 2020 Apr 16;[EPub Ahead of Print], NV Frey, S Gill, EO Hexner, S Schuster, S Nasta, A Loren, J Svoboda, E Stadtmauer, DJ Landsburg, A Mato, BL Levine, SF Lacey, JJ Melenhorst, E Veloso, A Gaymon, E Pequignot, X Shan, WT Hwang, CH June, DL PorterFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.